Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Loading
Home›
Research›
Investment Firms›
5AM Ventures
AddedFeb 13, 2024
UpdatedJun 28, 2026
5AM Ventures

5AM Ventures

Operating

5AM: A diversified biopharmaceutical investment fund pioneering in advanced life science innovations since 2002.

Location
Menlo Park, CA, US
Founded
2002
Firm
Compare
Portfolio
Employees
Website

Investments

Silence Therapeutics
Silence Therapeutics
Public

Total Raised

$248.7M

Rounds

6

Post Ipo Equity$120MFebruary 2024
MapLight Therapeutics
MapLight Therapeutics

Total Raised

$268.1M

Rounds

4

Series C$225MOctober 2023
Precede Biosciences
Precede Biosciences

Total Raised

$57M

Rounds

1

Series A$57MOctober 2023
Nvelop Therapeutics
Nvelop Therapeutics

Total Raised

$100M

Rounds

1

Seed$100MSeptember 2023
Radionetics Oncology
Radionetics Oncology

Total Raised

$82.5M

Rounds

2

Series A$52.5MAugust 2023
Seed$30MOctober 2021
Carmot Therapeutics
Carmot Therapeutics

Total Raised

$384.8M

Rounds

8

Series E$150MMay 2023
Spruce Biosciences
Spruce Biosciences
Public

Total Raised

$161.6M

Rounds

4

Post Ipo Equity$53.6MFebruary 2023
Ensoma
Ensoma

Total Raised

$205M

Rounds

3

Series B$85MJanuary 2023
Series A$70MFebruary 2021
Escient Pharmaceuticals
Escient Pharmaceuticals
Public

Total Raised

$237.5M

Rounds

3

Series C$120MNovember 2022
Novome Biotechnologies
Novome Biotechnologies

Total Raised

$83.1M

Rounds

6

Series B$43.5MSeptember 2022
CAMP4 Therapeutics
CAMP4 Therapeutics

Total Raised

$190M

Rounds

4

Series B$100MJuly 2022
Series A$45MJune 2021
Magnetic Insight
Magnetic Insight

Total Raised

$41.2M

Rounds

10

Series B$17MJune 2022
Pear Therapeutics
Pear Therapeutics
Public

Total Raised

$409M

Rounds

9

Post Ipo Equity$125MDecember 2021
Series D$80MDecember 2020
Expansion Therapeutics
Expansion Therapeutics

Total Raised

$142.2M

Rounds

3

Series B$80MSeptember 2021
RareCyte
RareCyte
Public

Total Raised

$76M

Rounds

5

Series G$24MSeptember 2021
Neurogastrx
Neurogastrx

Total Raised

$105M

Rounds

2

Series B$60MAugust 2021
Tmrw Life Sciences
Tmrw Life Sciences

Total Raised

$153.5M

Rounds

5

Series C$105MJuly 2021
Soteria Biotherapeutics
Soteria Biotherapeutics

Total Raised

$42M

Rounds

1

Series A$42MMay 2021
Entrada Therapeutics
Entrada Therapeutics
Public

Total Raised

$201.6M

Rounds

5

Series B$116MMarch 2021
Artiva Biotherapeutics
Artiva Biotherapeutics

Total Raised

$198M

Rounds

2

Series B$120MFebruary 2021
Kinaset Therapeutics
Kinaset Therapeutics

Total Raised

$41.5M

Rounds

2

Series A$40MNovember 2020